Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.43 |
| ▸ | CES1 | P23141 | 6/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16681872 | 0.87 | RIPK1 (0.44) | CES2CES1RIPK1ERN1CNR1 | |
| SCHEMBL153965 | 0.83 | CES2 (0.41) | CES2CES1RIPK1ERN1CNR1 | |
| SCHEMBL1884539 | 0.81 | CES2 (0.40) | CES2CES1RIPK1ERN1CNR1 | |
| SCHEMBL1560230 | 0.81 | RIPK1 (0.42) | CES2CES1RIPK1ERN1CNR1 | |
| SCHEMBL2566904 | 0.81 | CES2 (0.40) | CES2CES1RIPK1ERN1CNR1 | |
| SCHEMBL6863804 | 0.76 | CA1 (0.41) | CES2CES1TAAR1 | |
| SCHEMBL155393 | 0.76 | HSP90AB1 (0.46) | CES2CES1RIPK1ALDH1A1 | |
| SCHEMBL15160747 | 0.76 | RIPK1 (0.39) | CES2CES1RIPK1ERN1CNR1 | |
| SCHEMBL16965477 | 0.76 | RIPK1 (0.46) | CES2CES1RIPK1ERN1CNR1 | |
| SCHEMBL18698662 | 0.76 | RIPK1 (0.46) | CES2CES1RIPK1ERN1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797842-B2 | BY ASYMMETRICALLY REDUCING AN OPTICALLY ACTIVE IMINE, USING A HYDRIDE REDUCING AGENT TO CONVERT TO AN OPTICALLY ACTIVE SECONDARY AMINE, WHICH THEN UNDERGOES HYDROGENOLYSIS; HIGH OPTICAL PURITY, SIMPLE, EFFICIENT | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | MAP2K5, MAP2K4, MAP2K1 | CES2 2291/4885CES1 984/4885RIPK1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.